Merck's Strategic Expansion in North Carolina

In a significant boost to its manufacturing capabilities, Merck & Co Inc. has inaugurated a new vaccine manufacturing facility in Durham, North Carolina. This state-of-the-art plant, valued at $1 billion, complements the existing site and underscores Merck's commitment to enhancing its production infrastructure in the United States.

Investment in the Future of Healthcare

Sanat Chattopadhyay, President of Merck Manufacturing Division, emphasized the importance of this expansion. "This marks a pivotal moment in our journey to fortify our production and manufacturing prowess in the US," he stated. This move is part of Merck's broader investment strategy, with over $12 billion invested in the US since 2018 and an additional $8 billion planned by 2028.